Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

6986 results

Sort By:

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Study ID: NCT03907475
Start Date: 2019-07-16
End Date: 2026-06-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

115

Intervention / Treatment

Biopsy Procedure

Biospecimen Collection

Capecitabine

Carboplatin

Computed Tomography

Durvalumab

Echocardiography Test

Gemcitabine Hydrochloride

Nab-paclitaxel

Paclitaxel

Pegylated Liposomal Doxorubicin Hydrochloride

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Training in Evidence-based Treatments in Psycho-Oncology

Study ID: NCT05674357
Start Date: 2023-01-09
End Date: 2029-01-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

115

Intervention / Treatment

Individualized Evidence-Based Therapy in Cancer (Patients)

Training in Individualized Evidence-Based Therapy in Cancer (Therapists)

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

Study ID: NCT07030400
Start Date: 2025-06-05
End Date: 2028-06
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Bruton's tyrosine kinase inhibitor

B-Cell Lymphoma 2 Protein Inhibitor

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Source: clinicaltrials.gov

Share:
Add to list

Pancreatic Cancer Genetics

Study ID: NCT01102569
Start Date: 2008-01
End Date: 2027-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment
Sponsor

Columbia University

Source: clinicaltrials.gov

Share:
Add to list

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Study ID: NCT06879041
Start Date: 2025-03-10
End Date: 2029-04-16
Study Type

Interventional

Study Phase

Phase1

No. of Participants

134

Intervention / Treatment

More and more

AZDAHIKH

AZD2284

Sponsor

AstraZeneca

Source: clinicaltrials.gov

Share:
Add to list

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Study ID: NCT06190951
Start Date: 2024-09-18
End Date: 2031-04-23
Study Type

Interventional

Study Phase

Phase2

No. of Participants

150

Intervention / Treatment

cemiplimab

Fixed Dose Combination (FDC) cemiplimab+fianlimab

Placebo

Sponsor

Regeneron Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Study ID: NCT05715229
Start Date: 2023-09-29
End Date: 2026-04-28
Study Type

Interventional

Study Phase

Phase2

No. of Participants

108

Intervention / Treatment

Nivolumab

Ipilimumab

Carboplatin

Paclitaxel

Pemetrexed

Sponsor

Hackensack Meridian Health

Source: clinicaltrials.gov

Share:
Add to list

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Study ID: NCT07112053
Start Date: 2025-11-07
End Date: 2028-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

Capecitabine

Computed Tomography

Cyclin-Dependent Kinase 4 Inhibitor

Cyclin-Dependent Kinase 6 Inhibitor

F-18 16 Alpha-Fluoroestradiol

Hormone Therapy

Positron Emission Tomography

Ultrasound Imaging

Biopsy Procedure

Biospecimen Collection

Sponsor

University of Washington

Source: clinicaltrials.gov

Share:
Add to list

Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures

Study ID: NCT07225101
Start Date: 2025-11-01
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Phase4

No. of Participants

160

Intervention / Treatment

STRATAFIX PDS and Monocryl suture

Sponsor

University of Michigan

Source: clinicaltrials.gov

Share:
Add to list

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Study ID: NCT05455619
Start Date: 2022-08-26
End Date: 2026-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

52

Intervention / Treatment

Evexomostat

Sponsor

SynDevRx, Inc.

Source: clinicaltrials.gov

Share:
Add to list